BACKGROUND: Kaposi sarcoma-associated herpesvirus (KSHV) is the causal agent for Kaposi sarcoma (KS) and multicentric Castleman disease (MCD) in human immunodeficiency virus (HIV)-infected patients. Patients with KSHV-MCD develop fevers, wasting, hypoalbuminemia, cytopenias, and hyponatremia that are related to overproduction of KSHV-encoded viral interleukin (IL)-6 (vIL-6) and human IL-6 (hIL-6). METHODS: We identified 6 HIV-infected patients with KS or serological evidence of KSHV infection who had severe inflammatory MCD-like symptoms but in whom we could not diagnose MCD, and we hypothesized that these symptoms resulted from vIL-6 overproduction. Serum vIL-6 levels were assessed in these 6 patients and compared with levels in 8 control patients with symptomatic KSHV-MCD and 32 control patients with KS. KSHV viral load, serum hIL-6 level, and human IL-10 level were also evaluated. RESULTS: Patients with inflammatory MCD-like symptoms but without MCD had elevated vIL-6 levels, comparable with levels in patients with symptomatic KSHV-MCD, and had levels that were significantly greater than those in control patients with KS (P = .003). Elevated hIL-6, IL-10, and KSHV viral loads were also comparable to patients with symptomatic KSHV-MCD and significantly greater than those with KS. CONCLUSIONS: A subset of patients with HIV and KSHV co-infection, but without MCD, can develop severe systemic inflammatory symptoms associated with elevated levels of KSHV vIL-6, IL-6, and KSHV viral loads. Excess lytic activation of KSHV, production of the lytic gene product vIL6, and associated immunologic dysregulation may underlie the pathophysiology of these symptoms. This IL-6-related inflammatory syndrome is important to consider in critically ill patients with HIV and KSHV co-infection.
BACKGROUND:Kaposi sarcoma-associated herpesvirus (KSHV) is the causal agent for Kaposi sarcoma (KS) and multicentric Castleman disease (MCD) in humanimmunodeficiency virus (HIV)-infectedpatients. Patients with KSHV-MCD develop fevers, wasting, hypoalbuminemia, cytopenias, and hyponatremia that are related to overproduction of KSHV-encoded viral interleukin (IL)-6 (vIL-6) and humanIL-6 (hIL-6). METHODS: We identified 6 HIV-infectedpatients with KS or serological evidence of KSHV infection who had severe inflammatory MCD-like symptoms but in whom we could not diagnose MCD, and we hypothesized that these symptoms resulted from vIL-6 overproduction. Serum vIL-6 levels were assessed in these 6 patients and compared with levels in 8 control patients with symptomatic KSHV-MCD and 32 control patients with KS. KSHV viral load, serum hIL-6 level, and humanIL-10 level were also evaluated. RESULTS:Patients with inflammatory MCD-like symptoms but without MCD had elevated vIL-6 levels, comparable with levels in patients with symptomatic KSHV-MCD, and had levels that were significantly greater than those in control patients with KS (P = .003). Elevated hIL-6, IL-10, and KSHV viral loads were also comparable to patients with symptomatic KSHV-MCD and significantly greater than those with KS. CONCLUSIONS: A subset of patients with HIV and KSHV co-infection, but without MCD, can develop severe systemic inflammatory symptoms associated with elevated levels of KSHVvIL-6, IL-6, and KSHV viral loads. Excess lytic activation of KSHV, production of the lytic gene product vIL6, and associated immunologic dysregulation may underlie the pathophysiology of these symptoms. This IL-6-related inflammatory syndrome is important to consider in critically illpatients with HIV and KSHV co-infection.
Authors: Sílvia de Sanjosé; Vickie Marshall; Judit Solà; Virgilio Palacio; Rosa Almirall; James J Goedert; F Xavier Bosch; Denise Whitby Journal: Int J Cancer Date: 2002-03-01 Impact factor: 7.396
Authors: David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim Journal: Blood Date: 2017-01-13 Impact factor: 22.113
Authors: Salum J Lidenge; For Yue Tso; Owen Ngalamika; John R Ngowi; Yasaman Mortazavi; Eun Hee Kwon; Danielle M Shea; Veenu Minhas; Julius Mwaiselage; Charles Wood; John T West Journal: J Infect Dis Date: 2019-04-08 Impact factor: 5.226
Authors: Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Vickie Marshall; Victoria Wang; Denise Whitby; Stefania Pittaluga; Elaine S Jaffe; Corina Millo; Giovanna Tosato; Richard F Little; Seth M Steinberg; Irini Sereti; Robert Yarchoan Journal: Clin Infect Dis Date: 2015-12-12 Impact factor: 9.079